• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » U.K. pharma view on gov’t response to the Accelerated Access Review

U.K. pharma view on gov’t response to the Accelerated Access Review

November 8, 2017
CenterWatch Staff

The Government's response to the Accelerated Access Review (AAR) was published in a bid to dramatically speed up the time it takes for patients to benefit from ground-breaking treatments for conditions such as cancer, dementia and diabetes.

​The Government's announcement follows last year's final report from the indep​endently-chaired AAR, the aim of the Review was to make the U.K. “the fastest place in the world for the design, development and widespread adoption of medical innovations and stimulate new investment, jobs and economic growth to support the NHS."

In its response, the Government announced Sir Andrew Witty, former Chief Executive of GlaxoSmithKline, will lead the Accelerated Access Collaborative that will make decisions on which products should be granted access to the Accelerated Access Pathway.​

It also confirmed £86 million government funding to support innovators and the NHS in overcoming barriers to getting new, innovative technologies to patients quickly, in addition to improved NHS England commercial capacity and capability to deliver deals that achieve better value for the NHS and innovators​.

Commenting on the news, Dr. Richard Torbett, Executive Director of Commercial Policy at The ABPI, said: "The Government’s commitment to speeding up access to the most innovative medicines and treatments is very much welcome.

This should benefit thousands of NHS patients as well as delivering significant long-term savings for the health service if appropriate investment in these transformative therapies is made available.

Over the next decade, breakthrough personalized therapies have the potential to transform treatment for many diseases, from cancers to diabetes to dementia. It is incumbent on everyone to tear down the barriers which have prevented access to medical progress of this kind.

Sir Andrew Witty’s extensive pharmaceutical industry leadership and experience will be vital in helping to deliver a system which prioritizes patient access to transformative treatments. We are confident that the promise of making ground-breaking, cost-effective healthcare available for everyone, as quickly as possible, can be delivered through partnership with our industry, Government and the NHS."

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing